ArticleAmerican journal of surgery2022
Metastatic breast cancer: Who benefits from surgery?
Article in American journal of surgery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 22 citations in OpenAlex.
- The Role of Primary Tumor Resection in De Novo Bone-Only Metastatic Breast Cancer: A Propensity Score-Matched Analysis.Journal of surgical oncology · 2026Article
- Impact of axillary surgery on survival in de novo metastatic breast cancer with primary tumor resection.Breast cancer research and treatment · 2026Article
- Locally Ablative Therapies in Oligometastatic Breast Cancer.JAMA surgery · 2026Article
- Surgical Considerations for Patients With De Novo Metastatic Breast Cancer Based on Prognostic Group.The Journal of surgical research · 2025Article
- Impact of cancer-directed surgery for gastric cancer patients with lung metastasis: a prognosis analysis.Journal of gastrointestinal oncology · 2025Article
- Comparison of survival outcomes for patients with Stage III vs de novo Stage IV breast cancer.Cancer · 2025Article
- Development and validation of novel machine learning-based prognostic models and propensity score matching for comparison of surgical approaches in mucinous breast cancer.Frontiers in endocrinology · 2025Article
- Assessment of Treatment Sequence in Patients With Stage III Breast Cancer.The Journal of surgical research · 2024Article
- New Frontiers in the Treatment of Patients with HER2+ Cancer and Brain Metastases: Is Radiotherapy Always Useful?Cancers · 2024Review
- Personalized surgical recommendations and quantitative therapeutic insights for patients with metastatic breast cancer: Insights from deep learning.Cancer innovation · 2024Article
- Survival among patients with untreated metastatic breast cancer: "What if I do nothing?"Breast cancer research and treatment · 2024Article
- Analysis of the distinct features of metastasis male breast cancer and its effect on overall survival based on the SEER database compared with female breast cancer.Translational cancer research · 2023Article
- Loco-Regional Treatment of the Primary Tumor in De Novo Metastatic Breast Cancer Patients Undergoing Front-Line Chemotherapy.Cancers · 2022Article
- Survival Impact of Postoperative Primary Area Radiotherapy on De Novo Metastatic Breast Cancer: A Retrospective Study.Technology in cancer research & treatmentArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundWe sought to identify characteristics of metastatic breast cancer (MBC) patients who may benefit most from primary tumor resection.
methodsRecursive partitioning analysis (RPA) was used to categorize non-surgical patients with de novo MBC in the NCDB (2010-2015) into 3 groups (I/II/III) based on 3-year overall survival (OS). After bootstrapping (BS), group-level profiles were applied, and the association of surgery with OS was estimated using Cox proportional hazards models.
resultsAll patients benefitted from surgery (median OS, surgery vs no surgery): 72.7 vs 42.9 months, 47.3 vs 30.4 months, 23.8 vs 14.4 months (all p < 0.001) in BS-groups I, II, and III, respectively. After adjustment, surgery remained associated with improved OS (HR 0.52, 95% CI 0.50-0.55). The effect of surgery on OS differed quantitatively across groups.
conclusionPrognostic groups may inform the degree of benefit from surgery, with the greatest benefit seen in those with the most favorable survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.